Oncology dominates CRISPR landscape: GlobalData
Oncology accounts for 30 per cent of all active CRISPR drugs
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Casgevy
Top 20 global biopharma companies report 1.6 per cent per cent market cap growth to $3.67 tn in…
Four companies – Lilly (59.2 per cent), Novo Nordisk (51.5 per cent), Vertex Pharmaceuticals (41.4 per cent) and Regeneron…
US FDA gives record number of review designations to CRISPR drugs in 2023: GlobalData
Casgevy is the first CRISPR-based drug to receive marketing authorisation globally
US FDA approves Casgevy, cell-based gene therapy to treat transfusion-dependent beta-thalassemia
The approval signifies a second FDA-approved indication for Casgevy, as the product was also recently approved for the treatment…
Vertex Pharma poised to dominate global gene therapy market with first CRISPR approval: GlobalData
The global cell and gene therapy market is expected to reach $80 billion in 2029, with a high CAGR of 51.6 per cent between 2023…